OINDP / NASAL SUSPENSION DEVELOPMENT
For suitable MDI and DPI studies, collected or emitted-dose particles can be counted and classified by optical size. Targeted Raman measurements can identify selected materials and support comparisons between samples. Sampling, recovery and method suitability depend on the product and study design.
CORE API PSD EVIDENCE
Automated imaging identifies the particle population and Raman spectroscopy confirms API identity. The resulting ingredient-specific API particle-size distribution can be compared between Test and Reference products without relying on total suspension PSD alone.
Result: 2,671 Raman-confirmed API particles were measured, with a median circular-equivalent diameter (D50) of 2.35 µm.
Authentic GramRay i MK3 result: Raman-confirmed, size-calibrated API particles from a generic fluticasone nasal suspension.
STUDY EXECUTION
01
Product-specific method development
Sample preparation, settling, imaging, morphology targeting and Raman conditions developed around the actual product and study objective.
02
Comparative Test-vs.-Reference measurements
Controlled preparation and replicate measurements under comparable conditions.
03
Raman-confirmed particle populations
Ingredient-specific API PSD and, where relevant, characterization of complex particle structures.
04
Comparative analysis
Particle-size distributions, morphology, population metrics and study-specific comparisons.
05
Review-ready reporting
Traceable methods, particle images, Raman spectra, classifications and comparative outputs for integration into the broader development package.
A comparative MDRS work package can typically be executed and reviewed in approximately 6–12 weeks, depending on method readiness, study scope, batch design and replicate count.
An illustrative planning basis is 10 Test / Reference batches with 3+ replicates and approximately 100–150 automated measurements, including method development, pre-validation and controls.
Current measurement duration for this nasal-spray workflow is approximately 6 hours; the measurement plan is agreed for the product and study scope.
SizeID.bio can execute comparative MDRS studies directly for pharmaceutical developers or provide the specialist particle-Raman work package within an established CRO or analytical-laboratory program.
As a specialist analytical partner, we agree the MDRS scope, methods, reporting and data handoff with your team so the work package fits your broader IVBE strategy.
Our study design draws on more than two decades of particle-resolved Raman development experience. Methods are tailored to the product, comparator and regulatory objective.
The GramRay i MK3 platform combines automated high-count particle screening with targeted Raman measurement. Particle images, calibrated morphology, Raman spectra and classifications remain linked through reporting.
ADVANCED PARTICLE CHARACTERIZATION
Primary API PSD is a central descriptor of the formulated product, but it does not capture every aspect of particle organization. Morphology-based targeting can also exclude irregular API-associated structures before their chemistry is measured.
DeepMorph retains and prioritizes irregular candidate structures; Raman determines their chemistry. The workflow is optical population → DeepMorph candidate selection → targeted 2D Raman mapping → chemical classification. A DeepMorph-selected candidate is not automatically an AECP. Raman mapping provides the chemical ground truth: it confirms both API and excipient contributions in API–excipient composites, identifies API–API agglomerates without confirmed excipient contribution, and distinguishes other / non-AECP particle events.

Authentic example: conventional targeting → DeepMorph candidate retention → 2D Raman mapping confirming API and excipient chemistry within the composite particle.
EFFICIENT PARTICLE-RAMAN ANALYSIS
DeepMorph evaluates the complete optical particle population and directs Raman measurements according to the analytical question. High-count single-particle Raman measurements generate ingredient-specific API particle-size distributions, while a smaller population of irregular candidates is selected for full 2D Raman mapping to resolve complex particle chemistry.
25,140 particles
Optically screened and DeepMorph evaluated
API particle-size distribution
~1,500 API particles / routine run
Single-particle Raman confirmation
↓
Ingredient-specific API PSD
DeepMorph targets API-like particles without relying solely on simple morphology filters for enrichment. Raman confirms API identity before particles enter the API-specific size distribution.
Complex particle characterization
~500 candidates / routine run
Full 2D Raman mapping
↓
API–excipient composites · API–API agglomerates · other events
Irregular candidate structures are retained for spatially resolved Raman analysis rather than being excluded solely because of morphology.
In the illustrated dataset, only 550 of 25,140 optically screened particles — approximately 2.2% — required full 2D Raman mapping.
97.8% of the optical population therefore did not require full spatial Raman mapping.

Illustrative field from a generic fluticasone nasal suspension: green bounding boxes mark Raman-confirmed API particles in a 200 µm × 200 µm field of view.
TEST VS REFERENCE COMPARISON
In this example, the Reference and Generic products had free-API D50 values of 3.22 and 3.18 µm, respectively. The size distributions are characterized separately from complex composite structures.
Reference nasal suspension
Free API PSD · D50 3.22 µm · D90 6.81 µm
Generic nasal suspension
Free API PSD · D50 3.18 µm · D90 6.89 µm
Test and Reference samples are prepared and measured under comparable conditions, with replicate measurements and Raman-confirmed particle populations. Distribution-level comparisons and optional agglomeration or composite characterization are interpreted within the product-specific study design.
Ingredient-specific API PSD
Raman-confirmed Test-vs.-Reference API size distributions.
Complex-particle characterization
API association, agglomeration and composite structures where relevant to the product and study objective.
Traceable chemical verification
Particle images, morphology and Raman spectra remain linked from measurement through reporting.
Together, these measurements provide particle-resolved evidence for comparative characterization of Test and Reference nasal suspensions.
REGULATORY CONTEXT
MDRS supports ingredient-specific API particle-size characterization in formulated nasal suspensions within product-specific development approaches. SizeID.bio tailors the method to the product, comparator and study objective, and supplies documented comparative outputs for the broader IVBE / ANDA evidence package.
Nasal-suspension bioequivalence is a separate question from MDI/DPI foreign-particulate control and delivered-dose or aerodynamic performance testing. Ingredient-specific Raman sizing provides complementary evidence for the nasal study.
AECP analysis is not a standalone equivalence endpoint and does not alone establish Q3 equivalence. The MDRS work package contributes to the wider IVBE evidence program; it does not alone establish bioequivalence.
Share your Test and Reference products and development question. We can define the MDRS work package around the evidence your program needs, either directly or within an existing CRO or laboratory program.
Discuss your OINDP study
For product developers, CROs and analytical laboratories.
